Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

Key Inclusion Criteria: General Inclusion Criteria (all cohorts): * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Measurable disease per RECIST version 1.1 * Adequate hematology, renal and hepatic function * Left ventricular ejection fraction (LVEF) ≥ 50% * Patients with brain metastases may be enrolled only if treated, nonprogressive, asymptomatic and not taking high dose steroids for at least 4 weeks prior to Cycle 1 Day 1 (C1D1) * Individuals of childbearing potential who engage in heterosexual intercourse must agree to use method(s) of contraception, per protocol. * Tissue criteria: must provide sufficient, and adequate tumor tissue sample or agree to have a biopsy taken. Part A Specific Inclusion Criteria: zamzetoclax as monotherapy * Histologically or cytologically confirmed locally advanced or metastatic malignant solid tumor for which no standard therapy is available, standard therapy has failed, or for whom standard-of-care therapy is contraindicated. Cohorts B1 and C1 Specific Inclusion Criteria: * Histologically or cytologically confirmed unresectable metastatic or locally advanced disease following treatment for metastatic disease including an immune checkpoint inhibitor and a platinum-containing chemotherapy * Patients with actionable genomic alterations must have also received treatment with at least 1 approved therapy appropriate to the genomic alteration unless unavailable or contraindicated Cohorts B4 and C4 Specific Inclusio…